Literature DB >> 28093526

Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice.

Yi Zhou1,2, Huimei Chen2,3, Li Liu2,4, Xueqing Yu5, Galina K Sukhova2, Min Yang6, Vasileios C Kyttaris7, Isaac E Stillman8, Bruce Gelb9,10, Peter Libby2, George C Tsokos7, Guo-Ping Shi11.   

Abstract

Cysteinyl cathepsin K (CatK) is expressed in osteoclasts to mediate bone resorption, but is also inducible under inflammatory conditions. Faslpr mice on a C57BL/6 background develop spontaneous systemic lupus erythematosus-like manifestations. Although normal mouse kidneys expressed negligible CatK, those from Faslpr mice showed elevated CatK expression in the glomeruli and tubulointerstitial space. Faslpr mice also showed elevated serum CatK levels. CatK deficiency in Faslpr mice reduced all tested kidney pathologies, including glomerulus and tubulointerstitial scores, glomerulus complement C3 and IgG deposition, chemokine expression and macrophage infiltration, and serum autoantibodies. CatK contributed to Faslpr mouse autoimmunity and pathology in part by its activity in TLR-7 proteolytic processing and consequent regulatory T (Treg) cell biology. Elevated TLR7 expression and proteolytic processing in Faslpr mouse kidneys and Tregs showed significantly reduced levels in CatK-deficient mice, leading to increased spleen and kidney Treg content. Purified CD4+CD25highFoxp3+ Tregs from CatK-deficient mice doubled their immunosuppressive activity against T effector cells, compared with those from CatK-sufficient mice. In Faslpr mice, repopulation of purified Tregs from CatK-sufficient mice reduced spleen sizes, autoantibody titers, and glomerulus C3 and IgG deposition, and increased splenic and kidney Treg contents. Tregs from CatK-deficient mice had significantly more potency than CatK-sufficient Tregs in reducing spleen sizes, serum autoantibody titers, and glomerulus C3 deposition, and in increasing splenic and kidney Treg content. This study established a possible role of CatK in TLR7 proteolytic activation, Treg immunosuppressive activity, and lupus autoimmunity and pathology.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28093526      PMCID: PMC5321845          DOI: 10.4049/jimmunol.1501145

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

Review 1.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

Review 2.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

3.  Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice.

Authors:  Yanwen Qin; Xu Cao; Jun Guo; Yaozhong Zhang; Lili Pan; Hongjia Zhang; Huihua Li; Chaoshu Tang; Jie Du; Guo-Ping Shi
Journal:  Cardiovasc Res       Date:  2012-08-07       Impact factor: 10.787

4.  Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs.

Authors:  Daniela Hackl; Jakob Loschko; Tim Sparwasser; Wolfgang Reindl; Anne B Krug
Journal:  Eur J Immunol       Date:  2011-05       Impact factor: 5.532

5.  Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.

Authors:  B D Gelb; G P Shi; H A Chapman; R J Desnick
Journal:  Science       Date:  1996-08-30       Impact factor: 47.728

6.  Role of cathepsin K in structural changes in brachiocephalic artery during progression of atherosclerosis in apoE-deficient mice.

Authors:  Andriy O Samokhin; Andre Wong; Paul Saftig; Dieter Brömme
Journal:  Atherosclerosis       Date:  2008-03-04       Impact factor: 5.162

7.  Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9.

Authors:  Boyoun Park; Melanie M Brinkmann; Eric Spooner; Clarissa C Lee; You-Me Kim; Hidde L Ploegh
Journal:  Nat Immunol       Date:  2008-10-19       Impact factor: 25.606

Review 8.  Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Konstantia-Maria Chavele; Michael R Ehrenstein
Journal:  FEBS Lett       Date:  2011-08-04       Impact factor: 4.124

9.  The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor.

Authors:  Sarah E Ewald; Bettina L Lee; Laura Lau; Katherine E Wickliffe; Guo-Ping Shi; Harold A Chapman; Gregory M Barton
Journal:  Nature       Date:  2008-09-28       Impact factor: 49.962

10.  Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores.

Authors:  Marcella Funicello; Michela Novelli; Maurizio Ragni; Teresa Vottari; Cesare Cocuzza; Joaquin Soriano-Lopez; Chiara Chiellini; Federico Boschi; Pasquina Marzola; Pellegrino Masiello; Paul Saftig; Ferruccio Santini; Rene St-Jacques; Sylvie Desmarais; Nicolas Morin; Joseph Mancini; M David Percival; Aldo Pinchera; Margherita Maffei
Journal:  PLoS One       Date:  2007-08-01       Impact factor: 3.240

View more
  9 in total

1.  CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Lijun Zhang; Vasileios C Kyttaris; George C Tsokos; Isaac E Stillman; Takaharu Ichimura; Joseph V Bonventre; Peter Libby; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

Review 2.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

3.  Mendelian randomization analysis revealed potential causal factors for systemic lupus erythematosus.

Authors:  Xingbo Mo; Yufan Guo; Qiyu Qian; Mengzhen Fu; Shufeng Lei; Yonghong Zhang; Huan Zhang
Journal:  Immunology       Date:  2019-11-21       Impact factor: 7.397

Review 4.  Cysteine Cathepsins in Tumor-Associated Immune Cells.

Authors:  Tanja Jakoš; Anja Pišlar; Anahid Jewett; Janko Kos
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

Review 5.  Lysosomes as a therapeutic target.

Authors:  Srinivasa Reddy Bonam; Fengjuan Wang; Sylviane Muller
Journal:  Nat Rev Drug Discov       Date:  2019-09-02       Impact factor: 84.694

Review 6.  Targeting lysosomes in human disease: from basic research to clinical applications.

Authors:  Mengdie Cao; Xiangyuan Luo; Kongming Wu; Xingxing He
Journal:  Signal Transduct Target Ther       Date:  2021-11-08

Review 7.  Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy.

Authors:  Ran Gao; Guo-Ping Shi; Jing Wang
Journal:  Front Immunol       Date:  2022-03-17       Impact factor: 7.561

Review 8.  The Role of Cysteine Peptidases in Hematopoietic Stem Cell Differentiation and Modulation of Immune System Function.

Authors:  Milica Perišić Nanut; Urša Pečar Fonović; Tanja Jakoš; Janko Kos
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

Review 9.  Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.

Authors:  Janko Kos; Ana Mitrović; Milica Perišić Nanut; Anja Pišlar
Journal:  FEBS Open Bio       Date:  2022-02-03       Impact factor: 2.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.